retatrutide glp-1 gip glucagon receptor agonist just had its biggest data year yet. In 2026, Eli Lilly's triple GLP-1/GIP/glucagon posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight What Is Retatrutide (RETA)? The
Description
In clinical trials, common adverse reactions to GLP-1 class drugs include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation [30,31]
While high-fiber foods and proteins can trigger your body to release its own GLP-1 hormone, this indirect effect is far weaker than pharmaceutical GLP-1 agonists like semaglutide
Baseline C-reactive protein (CRP) 2.72 (1.15
Only 1 in 5 people with opioid use disorder and fewer than 8% of those with alcohol use disorder receive treatment
D.Van RaalteD
